Howard J Leonhardt is a Biomedical Engineer Inventor with over 100 issued patent claims. In the 1980’s, he developed the leading predictably compliant cardiovascular balloon catheters and in 1990’s the leading stent graft system for repair of aortic aneurysms, the first percutaneous heart valve, stem cell and micro energy delivery catheters and the first intravascular lung and biological pacemaker. Since 1999, his research focus has been on Organ Regeneration. In early 2001, he led a team that completed the first-in-man non-surgical stem cell repair of a human heart. He has an honorary PhD in Biomedical Engineering from the University of Northern California. He graduated from the International Trade Program in 1982 from Anoka Technical College in Minneapolis, Minnesota and has attended certificate courses at the University of Minnesota and UCLA. He operates research labs in Northern and Southern California as well as in Utah and incubator/accelerators with over 30 startups in the current portfolio; 24 of those are organ regeneration focused bases on his own inventions. Howard J Leonhardt is a Biomedical Engineer Inventor with over 100 issued patent claims. In the 1980’s, he developed the leading predictably compliant cardiovascular balloon catheters and in 1990’s the leading stent graft system for repair of aortic aneurysms, the first percutaneous heart valve, stem cell and micro energy delivery catheters and the first intravascular lung and biological pacemaker. Since 1999, his research focus has been on Organ Regeneration. In early 2001, he led a team that completed the first-in-man non-surgical stem cell repair of a human heart. He has an honorary PhD in Biomedical Engineering from the University of Northern California. He graduated from the International Trade Program in 1982 from Anoka Technical College in Minneapolis, Minnesota and has attended certificate courses at the University of Minnesota and UCLA. He operates research labs in Northern and Southern California as well as in Utah and incubator/accelerators with over 30 startups in the current portfolio; 24 of those are organ regeneration focused bases on his own inventions.

Gastroenterology